It’s a strategic blueprint, introducing pillars for success in the real world, drawing from the expertise of scientists from pharma, including GSK, Novartis, Eli Lilly and Company, Merck, AstraZeneca, Bayer | Crop Science, Pfizer, Recursion, Novo Nordisk, Sanofi, Relay Therapeutics, and others.
May 6, 2025 13:09We spoke to government experts from the National Institute of Environmental Health Sciences (NIEHS) and thought leaders from academia, including the University of Cambridge, the Broad Institute of MIT, and Harvard. This unprecedented industry-wide effort outlines a unified framework for adopting AI.
This initiative aligns with the FDA's recent announcement to phase out traditional animal testing in favor of more human-relevant methods. Our collective work provides a roadmap for integrating AI, ensuring safer and more efficient drug development processes.
